Catalyst Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Catalyst Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Catalyst Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Catalyst Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Catalyst Pharmaceuticals Inc (Catalyst) is a commercial-stage biopharmaceutical company. It focuses on in-licensing, developing and commercializing prescription drugs that target rare neurological and neuromuscular diseases. The company’s product portfolio includes Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in children and adults, Fycompa (perampanel) tablets and oral suspension, for the treatment of partial-onset seizures, and Agamree (vamorolone) oral suspension, a corticosteroid with a novel structure for the treatment of Duchenne Muscular Dystrophy (DMD). Catalyst sells its products through a field force and specialty pharmacies for distribution. The company operates in the US and through its subsidiary, in Ireland. Catalyst is headquartered in Coral Gables, Florida, the US.
Headquarters
United States of America
Address
355 Alhambra Circle, Suite 801, Coral Gables, Florida, 33134
Website
www.catalystpharma.com
Telephone
1 305 4203200
No of Employees
182
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CPRX (NASD)
Revenue (2024)
$589.0M
19.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
30.8%
(2024 vs 2023)
Market Cap*
$3.9B
Net Profit Margin (2024)
XYZ
9.2%
(2024 vs 2023)
* As of and is in US$
Catalyst Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Firdapse: Lambert-Eaton Myasthenic Syndrome (LEMS) | Firdapse |
| Agamree (Vamorolone): Duchenne Muscular Dystrophy (DMD) | Agamree |
| Fycompa: Focal Onset Seizures | Fycompa |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In October, the company's sub-licensee, KYE Pharmaceuticals, received Health Canada approval for AGAMREE for Duchenne muscular dystrophy (DMD). |
| 2025 | New Products/Services | In January, the company's sub-licensee DyDo Pharma launched Firdapse in Japan. |
| 2024 | Contracts/Agreements | In July, the company entered into a license, supply, and commercialization agreement with Kye Pharmaceuticals Inc for Agamree in Canada. |
Competitor Comparison
| Key Parameters | Catalyst Pharmaceuticals Inc | BioMarin Pharmaceutical Inc | Sarepta Therapeutics Inc | PTC Therapeutics Inc | ANI Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Coral Gables | San Rafael | Cambridge | Warren | Baudette |
| State/Province | Florida | California | Massachusetts | New Jersey | Minnesota |
| No. of Employees | 182 | 3,221 | 835 | 991 | 970 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Richard J. Daly | President; Chief Executive Officer; Director | Executive Board | 2024 | 65 |
| Michael W. Kalb | Executive Vice President; Chief Financial Officer; Treasurer | Senior Management | 2024 | 55 |
| Steven R. Miller, Ph.D. | Executive Vice President; Chief Operating Officer; Chief Scientific Officer | Senior Management | 2024 | 64 |
| Preethi Sundaram, Ph.D. | Chief Strategy Officer | Senior Management | 2022 | 50 |
| Brian Elsbernd | Chief Legal Officer; Chief Compliance Officer | Senior Management | 2019 | 62 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer